Synchron Raises $200M Series D to Advance BCI Commercialization
Synchron announced a $200 million Series D funding round to accelerate the commercialization of its brain-computer interface (BCI) system, Stentrode. Based in New York, the company will use the funds to expedite pivotal trials and support the launch of Stentrode.
Funding and Development Plans
This latest financing brings Synchron’s total capital raised to $345 million. The proceeds will also fuel the development of a next-generation brain interface and expand the company's Cognitive AI division in New York, which focuses on training models to decode brain signals in real time.
Expansion and Hiring
Synchron is expanding its team by hiring engineers, neuroscientists, and operators to advance next-generation BCIs. Additionally, a new engineering hub in San Diego has been established to work on advanced brain interface technology.
Investors and Participation
- Lead investor: Double Point Ventures
- Existing investors: ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, METIS
- New investors: Australian National Reconstruction Fund (NRF), T.Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, IQT
About Stentrode Technology
Stentrode is a unique brain-computer interface implanted through an endovascular approach. It detects motor intentions by capturing neural signals from blood vessels within the brain, specifically positioned on the surface of the motor cortex via the jugular vein.
Synchron states that its BCI is "the only one tapping into blood vessels to capture signals from the brain."
Author’s summary: Synchron secured $200M funding to fast-track its innovative vascular-implanted brain-computer interface and develop next-gen technologies, combining AI and neuroengineering advancements.